Sovran Advisors LLC Sells 25,471 Shares of Pfizer Inc. $PFE

Sovran Advisors LLC lowered its stake in Pfizer Inc. (NYSE:PFE) by 76.5% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 7,816 shares of the biopharmaceutical company’s stock after selling 25,471 shares during the quarter. Sovran Advisors LLC’s holdings in Pfizer were worth $200,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Gould Capital LLC lifted its position in shares of Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. bought a new stake in shares of Pfizer in the first quarter worth $27,000. North Capital Inc. bought a new stake in shares of Pfizer in the first quarter worth $28,000. Bayforest Capital Ltd bought a new stake in shares of Pfizer in the first quarter worth $28,000. Finally, Bernard Wealth Management Corp. bought a new stake in shares of Pfizer in the fourth quarter worth $30,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of research reports. Citigroup boosted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Morgan Stanley boosted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 6th. Berenberg Bank cut their price objective on shares of Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a research report on Thursday, May 29th. Bank of America boosted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Finally, Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $28.12.

Pfizer Trading Down 0.5%

PFE opened at $24.03 on Friday. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The company has a 50-day simple moving average of $24.63 and a 200 day simple moving average of $24.21. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $136.62 billion, a price-to-earnings ratio of 12.78, a P/E/G ratio of 0.85 and a beta of 0.55.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.2%. The ex-dividend date of this dividend was Friday, July 25th. Pfizer’s dividend payout ratio is currently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.